DARMSTADT, Germany, March 25, 2019 /PRNewswire/ --
-- MAVENCLAD(®) is now approved in 52 countries worldwide
-- Approval brings forward new treatment option with a novel mechanism for
highly active relapsing multiple sclerosis in Switzerland
-- Approval based on extensive clinical development program capturing more
than 10,000 patient years of safety data and up to 10 years of follow-up
in some patients
-- MAVENCLAD(®) provides the possibility of up to four years of disease
control with a maximum of 20 days of oral treatment administered over
Merck, a leading science and technology company, today announced that MAVENCLAD(®) (cladribine tablets) has been approved for the treatment of highly active relapsing remitting multiple sclerosis* (RRMS)() in Switzerland. MAVENCLAD(®) is the first treatment for RRMS that provides the possibility of up to four years of disease control with a maximum of 20 days of oral treatment administered over two years.
"The Swissmedic approval of MAVENCLAD is great news for patients in Switzerland with highly active relapsing remitting MS," said Luciano Rossetti, Head of Global Research & Development for the Biopharma business of Merck. "These patients have had limited treatment options and MAVENCLAD, now approved in 52 countries worldwide, represents an important new therapy with a novel mechanism as the first short-course oral treatment for relapsing remitting MS in Switzerland."
MAVENCLAD(®) has demonstrated durable clinical efficacy for up to four years across key measures of disease activity, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity. The approval of MAVENCLAD(®) is based on more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. The clinical development program included data from three placebo-controlled Phase III trials, CLARITY (pivotal efficacy study)(,) CLARITY EXTENSION() and ORACLE MS,() the Phase II ONWARD study;() and long-term follow-up data from the 8-year prospective registry, PREMIERE.() The efficacy and safety results of these studies allowed for a full characterization of the benefit-to-risk profile of MAVENCLAD(®).
"To receive a reliably effective therapy remains the most important consideration for patients," said Professor Ludwig Kappos, Chair, Neurology, University Hospital Basel, Switzerland. "The medium and long-term treatment risks ought to be as low as possible. Last but not least the treatment should be very compatible with a normal daily life. The approval of MAVENCLAD for highly active relapsing remitting multiple sclerosis by Swissmedic in Switzerland is good news because it extends the range of options for this group of MS patients with an oral treatment with proven, long-lasting effect."
In patients with high disease activity, post hoc analyses of the two-year Phase III CLARITY trial(2)(,) demonstrated that MAVENCLAD(®) reduced the annualized relapse rate by 67% and the risk of 6-month confirmed Expanded Disability Status Scale (EDSS) progression by 82% versus placebo. As demonstrated in the Phase III CLARITY EXTENSION study, no further MAVENCLAD(®) treatment was required in Years 3 and 4.() MAVENCLAD(®) has a well-characterized safety profile, with up to ten years of observation in some patients and no reported cases of progressive multifocal leukoencephalopathy (PML) in MS. The most clinically relevant adverse reactions were lymphopenia and herpes zoster. Lymphocyte counts must be assessed before, and during, treatment with MAVENCLAD(®). MAVENCLAD(® )is contraindicated in certain groups including immunocompromised patients and pregnant women.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe [http://www.merckgroup.com/subscribe] to register online, change your selection or discontinue this service.
MAVENCLAD(®) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD(®) for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD(®) has since then been approved in more than 50 countries, including Canada and Australia. MAVENCLAD(®) is currently under clinical investigation and not yet approved for the treatment for any use in the United States.
Visit www.MAVENCLAD.com [http://www.mavenclad.com/] for more information.
The clinical development program for cladribine tablets includes:
-- The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year
Phase III placebo-controlled study designed to evaluate the efficacy and
safety of cladribine tablets as a monotherapy in patients with RRMS.
-- The CLARITY extension study: a Phase III placebo-controlled study
following on from the CLARITY study, which evaluated the safety and
exploratory efficacy of cladribine tablets over two additional years
beyond the two-year CLARITY study, according to the treatment assignment
scheme for years 3 and 4.
-- The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III
placebo-controlled study designed to evaluate the efficacy and safety of
cladribine tablets as a monotherapy in patients at risk of developing MS
(patients who have experienced a first clinical event suggestive of MS).
-- The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in Patients
With Active Relapsing Disease) study: a Phase II placebo-controlled
study designed primarily to evaluate the safety and tolerability of
adding cladribine tablets treatment to patients with relapsing forms of
MS, who have experienced breakthrough disease while on established
-- PREMIERE (Prospective Observational Long-term Safety Registry of
Multiple Sclerosis) study: a long-term observational follow-up safety
registry of MS patients who participated in cladribine tablets clinical
In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. Adverse Events reported in other clinical studies were similar.(2)
Swiss Indication and Important Safety Information
Mavenclad(®) (10 mg cladribine)
I: Adult patients with highly active relapsing-remitting multiple sclerosis (MS), as defined by clinical or imaging findings. PO: Dose of 3.5 mg/kg body weight over 2 years, administered as 1 treatment phase of 1.75 mg/kg per year. CI: Hypersensitivity to cladribine or any of the excipients. Infection with the human immunodeficiency virus (HIV). Severe active infections, active chronic infection (e.g. tuberculosis or hepatitis). Initiation of treatment in immunocompromised patients. Existing active malignant disease. History of progressive multifocal leukoencephalopathy. Moderate or severe impairment of renal function. Children and adolescents under 18 years. Pregnancy and breast-feeding. W: General: Not recommended in patients with inactive disease or stabilised on established therapy. No more than 2 annual treatment phases within 4 years. Haematological monitoring: The lymphocyte count must be determined before the start of treatment with Mavenclad in year 1 and year 2, as well as 2 and 6 months after initiation of treatment in each year of treatment. Infections: Cladribine can weaken the body's immune system and potentially increase the likelihood of infection. Patients with lymphocyte counts below 500 cells/mm(3) must be actively monitored for signs and symptoms of infection, especially herpes zoster. Malignant disease: Cladribine interferes with DNA synthesis and has an immunosuppressive effect. Contraception: Reliable contraceptive methods must be used during treatment with cladribine and for at least 6 months after the last dose. Blood transfusions: In patients requiring blood transfusions, irradiation of the cellular blood components is recommended prior to transfusion. Switching to cladribine and from cladribine to other medicinal products: Before starting treatment with Mavenclad, the mechanism of action and duration of action of the other medicinal product should be taken into account. Renal disease: Mavenclad must not be used in cases of moderate or severe impairment of renal function. Hepatic disease: Mavenclad is not recommended in cases of moderate or severe impairment of liver function. Fructose intolerance: Patients with fructose intolerance should not take Mavenclad. IA: Mavenclad contains hydroxypropylbetadex, which may be able to form complexes with other medicinal products and hence lead to increased bioavailability of these medicinal products. Haematotoxic or immunosuppressive medicines (methotrexate, cyclophosphamide, ciclosporin, azathioprine, corticosteroids). Other disease-modifying drugs. Haematotoxic medicines (carbamazepine). Live vaccines and live attenuated vaccines. Potent inhibitors of ENT1, CNT3 and BCRP transporters (such as dilazep, nifedipine, nimodipine, cilostazol, sulindac, reserpine). Potent inducers of BCRP and P-gp transporters (e.g. corticosteroids and rifampicin, St. John's wort). Hormonal contraceptives. Most common UE: lymphopenia, oral herpes, dermatomal herpes zoster, reduction in neutrophil count, rash, alopecia. P: Mavenclad 10 mg: 1, 4 or 6 tablets. [A] For detailed information, see www.swissmedicinfo.ch [http://www.swissmedicinfo.ch/]. FEB19
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
Merck in Multiple Sclerosis
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). Merck's current portfolio includes two products for the treatment of relapsing MS, with a robust pipeline focusing on discovering new therapies that have the potential to modulate key pathogenic mechanisms in MS. Merck aims to improve the lives of those living with MS, by addressing areas of unmet medical needs.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2018, Merck generated sales of EUR 14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
* Defined as: patients with one relapse during the previous year and >= 1 T1 Gd+ lesion or >= 9 T2 lesions while on therapy with other disease modifying drugs (DMD); OR patients with >= 2 or more relapses in the previous year, whether on DMD treatment or not.
 MAVENCLAD(®) Summary of Product Characteristics February 2019
 Giovannoni G, Comi G, Cook S et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. 2010 New England Journal of Medicine 362:416-426
 Giovannoni G et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011; 10:329-337
 EU Clinical Trials Register. A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY). Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/results [https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/results]. Last accessed March 2019
 Leist T, Comi G, Cree B et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 2014; 13: 257-67
 EU Clinical Trials Register. A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Sclerosis Subjects with Active Disease. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003366-33/results [https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003366-33/results]. Last accessed March 2019
 Schreiner T, Miravalle A. Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine. Journal of Central Nervous System Disease. 2012; 4: 1-14
 Giovannoni G, Sorensen P, Cook S et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. 2018 Multiple Sclerosis Journal 1-9 [Epub ahead of print]
 Giovannoni G, Sorensen P, Cook S et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. 2018 Multiple Sclerosis Journal 24(12) 1594-1604
+49 151 1454 2694